The vaginal microbiota and innate immunity after local excisional treatment for cervical intraepithelial neoplasia.
Cervical intraepithelial neoplasia
Lactobacillus
Metataxonomics
Mucosal immunity
Vaginal microbiota
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
04 11 2021
04 11 2021
Historique:
received:
29
01
2021
accepted:
23
09
2021
entrez:
5
11
2021
pubmed:
6
11
2021
medline:
22
2
2022
Statut:
epublish
Résumé
Vaginal microbiota (VMB) composition is altered in women with cervical intra-epithelial neoplasia (CIN) compared to healthy controls and is associated with disease progression. However, the impact of CIN excision on the VMB and innate immunity is not known. This observational study aims to explore the impact of CIN excision on the VMB, antimicrobial peptides (AMP) and proinflammatory cytokines. We sampled 103 non-pregnant, premenopausal women at the time of excisional treatment for CIN and at their 6-month follow-up visit. A further 39 untreated controls with normal cytology were also sampled. We used metataxonomics to group vaginal swab samples into community state types (CSTs) and ELISA to quantify cytokine and AMP levels in matched vaginal secretions. Analyses were performed to compare the bacterial composition and immune analyte levels before and after CIN excision and in healthy controls. Women with CIN had significantly higher rates of Lactobacillus species depletion pre-treatment compared to healthy controls (CST IV 21/103, 20% vs 1/39, 3%, p = 0.0081). Excision did not change the VMB composition, with CST IV remaining significantly more prevalent after excision compared to untreated, healthy controls (CST IV 19/103, 20% vs 1/39, 3%, p = 0.0142). Prevotella bivia and Sneathia amnii were significantly higher in samples before treatment compared to untreated controls, and Prevotella bivia remained significantly higher amongst the treated, with less Lactobacillus crispatus compared to untreated controls. IL-1β and IL-8 remained significantly elevated pre- (p < 0.0001 and p = 0.0014, respectively) and post-treatment (p < 0.0001 and p = 0.0035, respectively) compared to untreated controls. Levels of human beta-defensin-1 and secretory leukocyte protease inhibitor were both significantly reduced following CIN excision (p < 0.0001); however, their levels remained lower than controls post-treatment. Women with CIN have an increased prevalence of Lactobacillus sp. depletion, high-diversity VMB composition, and higher levels of proinflammatory cytokines and AMPs compared to normal controls. Surgical excision of the disease reduces levels of vaginal AMPs but does not alter VMB composition or cytokine levels. These findings suggest that women with CIN have an inherent predisposition to a high-diversity proinflammatory environment that is not corrected by disease excision. The failure to re-establish a Lactobacillus-enriched CST may explain why women remain at high risk of pre-invasive and invasive disease recurrence.
Sections du résumé
BACKGROUND
Vaginal microbiota (VMB) composition is altered in women with cervical intra-epithelial neoplasia (CIN) compared to healthy controls and is associated with disease progression. However, the impact of CIN excision on the VMB and innate immunity is not known. This observational study aims to explore the impact of CIN excision on the VMB, antimicrobial peptides (AMP) and proinflammatory cytokines.
METHODS
We sampled 103 non-pregnant, premenopausal women at the time of excisional treatment for CIN and at their 6-month follow-up visit. A further 39 untreated controls with normal cytology were also sampled. We used metataxonomics to group vaginal swab samples into community state types (CSTs) and ELISA to quantify cytokine and AMP levels in matched vaginal secretions. Analyses were performed to compare the bacterial composition and immune analyte levels before and after CIN excision and in healthy controls.
RESULTS
Women with CIN had significantly higher rates of Lactobacillus species depletion pre-treatment compared to healthy controls (CST IV 21/103, 20% vs 1/39, 3%, p = 0.0081). Excision did not change the VMB composition, with CST IV remaining significantly more prevalent after excision compared to untreated, healthy controls (CST IV 19/103, 20% vs 1/39, 3%, p = 0.0142). Prevotella bivia and Sneathia amnii were significantly higher in samples before treatment compared to untreated controls, and Prevotella bivia remained significantly higher amongst the treated, with less Lactobacillus crispatus compared to untreated controls. IL-1β and IL-8 remained significantly elevated pre- (p < 0.0001 and p = 0.0014, respectively) and post-treatment (p < 0.0001 and p = 0.0035, respectively) compared to untreated controls. Levels of human beta-defensin-1 and secretory leukocyte protease inhibitor were both significantly reduced following CIN excision (p < 0.0001); however, their levels remained lower than controls post-treatment.
CONCLUSIONS
Women with CIN have an increased prevalence of Lactobacillus sp. depletion, high-diversity VMB composition, and higher levels of proinflammatory cytokines and AMPs compared to normal controls. Surgical excision of the disease reduces levels of vaginal AMPs but does not alter VMB composition or cytokine levels. These findings suggest that women with CIN have an inherent predisposition to a high-diversity proinflammatory environment that is not corrected by disease excision. The failure to re-establish a Lactobacillus-enriched CST may explain why women remain at high risk of pre-invasive and invasive disease recurrence.
Identifiants
pubmed: 34736529
doi: 10.1186/s13073-021-00977-w
pii: 10.1186/s13073-021-00977-w
pmc: PMC8567681
doi:
Substances chimiques
Antimicrobial Peptides
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
176Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
BJOG. 2010 Nov;117(12):1468-74
pubmed: 20840527
Sci Rep. 2017 Aug 31;7(1):10200
pubmed: 28860468
J Infect Dis. 2005 Nov 15;192(10):1731-40
pubmed: 16235171
Oncol Lett. 2018 Dec;16(6):7035-7047
pubmed: 30546437
Cell Host Microbe. 2017 Jan 11;21(1):97-105
pubmed: 28017660
J Immunol. 2001 Jul 1;167(1):497-504
pubmed: 11418688
Microbiome. 2016 Nov 1;4(1):58
pubmed: 27802830
J Infect Dis. 2014 Dec 1;210(11):1723-33
pubmed: 24943724
Probiotics Antimicrob Proteins. 2018 Jun;10(2):236-242
pubmed: 29071554
Am J Obstet Gynecol. 2008 Jun;198(6):628.e1-7
pubmed: 18295180
Front Cell Infect Microbiol. 2020 Apr 15;10:129
pubmed: 32351902
Nat Med. 2019 Oct;25(10):1500-1504
pubmed: 31591599
Lancet Oncol. 2017 Dec;18(12):1665-1679
pubmed: 29126708
Sex Transm Dis. 2012 Aug;39(8):591-7
pubmed: 22801340
Ann Oncol. 2020 Feb;31(2):213-227
pubmed: 31959338
Int J Cancer. 2009 Mar 15;124(6):1379-83
pubmed: 19089920
Bioinformatics. 2010 Mar 15;26(6):715-21
pubmed: 20130030
Transl Res. 2017 Jan;179:168-182
pubmed: 27477083
BMC Genomics. 2012;13 Suppl 8:S17
pubmed: 23282177
BMC Womens Health. 2019 Feb 6;19(1):30
pubmed: 30728029
Obstet Gynecol. 2007 May;109(5):1123-8
pubmed: 17470593
Mucosal Immunol. 2017 Sep;10(5):1310-1319
pubmed: 28120845
Oncol Lett. 2015 Mar;9(3):1015-1026
pubmed: 25663851
Sci Rep. 2019 May 14;9(1):7333
pubmed: 31089160
PLoS One. 2013 May 22;8(5):e63514
pubmed: 23717441
Front Microbiol. 2018 Oct 08;9:2181
pubmed: 30349508
J Clin Pathol. 2002 Apr;55(4):244-65
pubmed: 11919208
Curr Opin Infect Dis. 2020 Feb;33(1):59-65
pubmed: 31789672
J Immunol Methods. 2012 Aug 31;382(1-2):211-5
pubmed: 22677266
FEMS Immunol Med Microbiol. 2006 Dec;48(3):424-32
pubmed: 17059467
Curr Probl Dermatol. 2014;45:58-74
pubmed: 24643178
Sci Transl Med. 2016 Aug 3;8(350):350ra102
pubmed: 27488896
Mol Hum Reprod. 2007 Apr;13(4):243-50
pubmed: 17314118
Appl Environ Microbiol. 2007 Aug;73(16):5261-7
pubmed: 17586664
Front Immunol. 2018 Mar 01;9:376
pubmed: 29545798
BMJ. 2008 Sep 18;337:a1284
pubmed: 18801868
Sci Rep. 2018 Mar 21;8(1):4923
pubmed: 29563617
Cancer Control. 2018 Jan-Dec;25(1):1073274818798598
pubmed: 30180755
BMJ. 2014 Jan 14;348:f7361
pubmed: 24423603
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
J Clin Invest. 1998 Apr 15;101(8):1633-42
pubmed: 9541493
J Infect Dis. 2011 Aug 1;204(3):391-9
pubmed: 21730203
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4680-7
pubmed: 20534435
Oncol Rep. 2013 May;29(5):1962-8
pubmed: 23467841
Nat Commun. 2020 Apr 24;11(1):1999
pubmed: 32332850
BJOG. 2020 Jan;127(2):171-180
pubmed: 31237400
Sci Rep. 2018 May 15;8(1):7593
pubmed: 29765068
Clin Microbiol Infect. 2015 Jul;21(7):674.e1-9
pubmed: 25752224
J Gene Med. 2004 Nov;6(11):1281-9
pubmed: 15368588
Sex Transm Infect. 2009 Aug;85(4):242-8
pubmed: 19004865
Am J Reprod Immunol. 2015 Jun;73(6):536-44
pubmed: 25559229
BJOG. 2012 May;119(6):678-84
pubmed: 22313794
Menopause. 2014 May;21(5):450-8
pubmed: 24080849
Virol J. 2006 Sep 08;3:75
pubmed: 16961924
Sci Rep. 2015 Nov 17;5:16865
pubmed: 26574055
J Reprod Immunol. 2015 Jun;109:74-83
pubmed: 25721621
Infect Immun. 2014 Apr;82(4):1657-65
pubmed: 24491573
BMC Infect Dis. 2014 Aug 28;14:471
pubmed: 25169082
Am J Obstet Gynecol. 2007 Dec;197(6):613.e1-3
pubmed: 17678865
Cancer Prev Res (Phila). 2016 May;9(5):357-66
pubmed: 26935422
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Acta Obstet Gynecol Scand. 2012 Sep;91(9):1103-8
pubmed: 22670621
PLoS One. 2016 Apr 26;11(4):e0153274
pubmed: 27115350
J Biol Chem. 2007 Jan 19;282(3):1819-29
pubmed: 17071614
BMJ. 2014 Oct 28;349:g6192
pubmed: 25352501
BMC Genomics. 2012;13 Suppl 8:S4
pubmed: 23281612
Eur J Obstet Gynecol Reprod Biol. 1995 Mar;59(1):95-101
pubmed: 7781866
Cochrane Database Syst Rev. 2017 Nov 02;11:CD012847
pubmed: 29095502
BMJ. 2016 Jul 28;354:i3633
pubmed: 27469988
Lancet. 2006 Feb 11;367(9509):489-98
pubmed: 16473126
Cancer Med. 2018 May;7(5):2172-2179
pubmed: 29608253
PLoS One. 2013 Sep 04;8(9):e73055
pubmed: 24023807
BMJ. 2019 Feb 6;364:l240
pubmed: 30728133
Int J Gynaecol Obstet. 2015 Feb;128(2):141-7
pubmed: 25444615
Int J Cancer. 2013 Sep 1;133(5):1187-96
pubmed: 23436563
PLoS Pathog. 2020 Mar 26;16(3):e1008376
pubmed: 32214382
EBioMedicine. 2019 Jun;44:675-690
pubmed: 31027917
Mem Inst Oswaldo Cruz. 2014 Nov;109(7):918-22
pubmed: 25410996
BJOG. 2011 May;118(6):685-92
pubmed: 21429068
BMJ. 2007 Nov 24;335(7629):1077
pubmed: 17959735
J Clin Invest. 1995 Jul;96(1):456-64
pubmed: 7615818